Stroke therapy: is spironolactone the Holy Grail?
Dorrance
Anne M
AM
Department of Pharmacology and Toxicology, B346 Life Sciences Building, Michigan State University, East Lansing, Michigan 48824, USA. dorranc3@msu.edu
D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D018696:Neuroprotective Agents / Q000627:therapeutic use; D018161:Receptors, Mineralocorticoid / Q000502:physiology; D013148:Spironolactone / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy* / Q000209:etiology
D000451:Mineralocorticoid Receptor Antagonists; D018696:Neuroprotective Agents; D018161:Receptors, Mineralocorticoid; D013148:Spironolactone